Order Article Reprints

Dalens L, Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, Chevrier S, Mananet H, Derangère V, et al. Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. International Journal of Molecular Sciences. 2023; 24(8):7592. https://doi.org/10.3390/ijms24087592

Dalens, Lorraine, Julie Lecuelle, Laure Favier, Cléa Fraisse, Aurélie Lagrange, Courèche Kaderbhai, Romain Boidot, Sandy Chevrier, Hugo Mananet, Valentin Derangère, and et al. 2023. "Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type" International Journal of Molecular Sciences 24, no. 8: 7592. https://doi.org/10.3390/ijms24087592

Dalens, L., Lecuelle, J., Favier, L., Fraisse, C., Lagrange, A., Kaderbhai, C., Boidot, R., Chevrier, S., Mananet, H., Derangère, V., Truntzer, C., & Ghiringhelli, F. (2023). Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. International Journal of Molecular Sciences, 24(8), 7592. https://doi.org/10.3390/ijms24087592